HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Abstract
Several large population-based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer disease (AD). However, other studies with drugs of the same class have shown no beneficial clinical effects. To determine whether certain DHPs are able to impact underlying disease processes in AD (specifically the accumulation of the Alzheimer Aβ peptide), we investigated the effect of several antihypertensive DHPs and non-DHP CCBs on Aβ production. Among the antihypertensive DHPs tested, a few, including nilvadipine, nitrendipine and amlodipine inhibited Aβ production in vitro, whereas others had no effect or raised Aβ levels. In vivo, nilvadipine and nitrendipine acutely reduced brain Aβ levels in a transgenic mouse model of AD (Tg PS1/APPsw) and improved Aβ clearance across the blood-brain barrier (BBB), whereas amlodipine and nifedipine were ineffective showing that the Aβ-lowering activity of the DHPs is independent of their antihypertensive activity. Chronic oral treatment with nilvadipine decreased Aβ burden in the brains of Tg APPsw (Tg2576) and Tg PS1/APPsw mice, and also improved learning abilities and spatial memory. Our data suggest that the clinical benefit conferred by certain antihypertensive DHPs against AD is unrelated to their antihypertensive activity, but rely on their ability to lower brain Aβ accumulation by affecting both Aβ production and Aβ clearance across the BBB.
AuthorsDaniel Paris, Corbin Bachmeier, Nikunj Patel, Amita Quadros, Claude-Henry Volmar, Vincent Laporte, Jim Ganey, David Beaulieu-Abdelahad, Ghania Ait-Ghezala, Fiona Crawford, Michael J Mullan
JournalMolecular medicine (Cambridge, Mass.) (Mol Med) 2011 Mar-Apr Vol. 17 Issue 3-4 Pg. 149-62 ISSN: 1528-3658 [Electronic] England
PMID21170472 (Publication Type: Journal Article)
Chemical References
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Dihydropyridines
  • nilvadipine
  • Amlodipine
  • Nitrendipine
  • Nifedipine
Topics
  • Alzheimer Disease (genetics, metabolism, prevention & control)
  • Amlodipine (pharmacology)
  • Amyloid beta-Peptides (genetics, metabolism)
  • Amyloid beta-Protein Precursor (genetics, metabolism)
  • Animals
  • Antihypertensive Agents (pharmacology)
  • Blood-Brain Barrier (drug effects, metabolism)
  • Blotting, Western
  • Brain (drug effects, metabolism, physiopathology)
  • CHO Cells
  • Calcium Channel Blockers (pharmacology)
  • Cell Line
  • Cell Line, Tumor
  • Cricetinae
  • Cricetulus
  • Dihydropyridines (pharmacology)
  • Dose-Response Relationship, Drug
  • Humans
  • Maze Learning (drug effects)
  • Memory (drug effects)
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Nifedipine (analogs & derivatives, pharmacology)
  • Nitrendipine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: